FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304892381> ?p ?o ?g. }

• W4304892381 endingPage "457" @default.
• W4304892381 startingPage "452" @default.
• W4304892381 abstract "Uterine serous carcinoma is a rare but aggressive subtype of endometrial adenocarcinoma. Our objective was to compare adjuvant treatment strategies for patients with early stage uterine serous carcinoma.This multi-institutional, retrospective cohort study evaluated patients with early stage uterine serous carcinoma. Patients with FIGO Stage IA-II disease after surgery, whose tumors had serous or any mixed serous/non-serous histology were included. Patients with carcinosarcoma were excluded. Clinical data were abstracted from local medical records. Summary statistics, Fisher's exact, and Kruskal-Wallis tests were used to analyze demographic and clinical characteristics. Univariable and multivariable analyses were performed for recurrence-free and overall survival.There were 737 patients included. Most patients had Stage IA disease (75%), 49% of which had no myometrial invasion. Only 164 (24%) tumors had lymphatic/vascular space invasion. Adjuvant treatment varied: 22% received no adjuvant therapy, 17% had chemotherapy alone, 19% had cuff brachytherapy, 35% had cuff brachytherapy with chemotherapy, and 6% underwent pelvic radiation. Adjuvant treatment was significantly associated with a decreased risk of recurrence (p = 0.04). Compared with no adjuvant therapy, patients who received brachytherapy or brachytherapy/chemotherapy had improved recurrence-free survival (HR 0.59, 95% CI 0.40-0.86; HR 0.65, 95% CI 0.49-0.88, respectively) and overall survival (HR 0.53, 95% CI 0.35-0.79; HR 0.49, 95% CI 0.35-0.69, respectively). Improved survival with brachytherapy and brachytherapy/chemotherapy persisted on multivariable analyses. Chemotherapy alone was also associated with improved overall survival compared with no adjuvant treatment (HR 0.55, 95% CI 0.37-0.81).Adjuvant therapy was associated with a decreased risk of recurrence relative to observation alone. Adjuvant cuff brachytherapy with and without chemotherapy was associated with improved survival outcomes in patients with early stage uterine serous carcinoma." @default.
• W4304892381 created "2022-10-13" @default.
• W4304892381 creator A5026269100 @default.
• W4304892381 creator A5029020419 @default.
• W4304892381 creator A5033305052 @default.
• W4304892381 creator A5041813027 @default.
• W4304892381 creator A5045683633 @default.
• W4304892381 creator A5045750849 @default.
• W4304892381 creator A5052515933 @default.
• W4304892381 creator A5067980172 @default.
• W4304892381 creator A5072607824 @default.
• W4304892381 creator A5080656521 @default.
• W4304892381 creator A5085369592 @default.
• W4304892381 creator A5090168202 @default.
• W4304892381 date "2022-12-01" @default.
• W4304892381 modified "2023-10-16" @default.
• W4304892381 title "Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study" @default.
• W4304892381 cites W1973873786 @default.
• W4304892381 cites W1981671145 @default.
• W4304892381 cites W2006762762 @default.
• W4304892381 cites W2006864961 @default.
• W4304892381 cites W2013620685 @default.
• W4304892381 cites W2038981426 @default.
• W4304892381 cites W2046089575 @default.
• W4304892381 cites W2065949107 @default.
• W4304892381 cites W2089253083 @default.
• W4304892381 cites W2090235959 @default.
• W4304892381 cites W2093274439 @default.
• W4304892381 cites W2115516019 @default.
• W4304892381 cites W2118510249 @default.
• W4304892381 cites W2218197966 @default.
• W4304892381 cites W2598436360 @default.
• W4304892381 cites W2611907288 @default.
• W4304892381 cites W2791829934 @default.
• W4304892381 cites W2937778512 @default.
• W4304892381 cites W3006709632 @default.
• W4304892381 cites W3043805805 @default.
• W4304892381 cites W3044642812 @default.
• W4304892381 cites W3047152751 @default.
• W4304892381 cites W3119005666 @default.
• W4304892381 cites W4238920897 @default.
• W4304892381 doi "https://doi.org/10.1016/j.ygyno.2022.09.025" @default.
• W4304892381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36243601" @default.
• W4304892381 hasPublicationYear "2022" @default.
• W4304892381 type Work @default.
• W4304892381 citedByCount "0" @default.
• W4304892381 crossrefType "journal-article" @default.
• W4304892381 hasAuthorship W4304892381A5026269100 @default.
• W4304892381 hasAuthorship W4304892381A5029020419 @default.
• W4304892381 hasAuthorship W4304892381A5033305052 @default.
• W4304892381 hasAuthorship W4304892381A5041813027 @default.
• W4304892381 hasAuthorship W4304892381A5045683633 @default.
• W4304892381 hasAuthorship W4304892381A5045750849 @default.
• W4304892381 hasAuthorship W4304892381A5052515933 @default.
• W4304892381 hasAuthorship W4304892381A5067980172 @default.
• W4304892381 hasAuthorship W4304892381A5072607824 @default.
• W4304892381 hasAuthorship W4304892381A5080656521 @default.
• W4304892381 hasAuthorship W4304892381A5085369592 @default.
• W4304892381 hasAuthorship W4304892381A5090168202 @default.
• W4304892381 hasConcept C121608353 @default.
• W4304892381 hasConcept C126322002 @default.
• W4304892381 hasConcept C141071460 @default.
• W4304892381 hasConcept C143998085 @default.
• W4304892381 hasConcept C146357865 @default.
• W4304892381 hasConcept C150173356 @default.
• W4304892381 hasConcept C151730666 @default.
• W4304892381 hasConcept C2776694085 @default.
• W4304892381 hasConcept C2777416452 @default.
• W4304892381 hasConcept C2777546739 @default.
• W4304892381 hasConcept C2777632260 @default.
• W4304892381 hasConcept C2777982462 @default.
• W4304892381 hasConcept C2778938455 @default.
• W4304892381 hasConcept C2780427987 @default.
• W4304892381 hasConcept C509974204 @default.
• W4304892381 hasConcept C71924100 @default.
• W4304892381 hasConcept C86803240 @default.
• W4304892381 hasConceptScore W4304892381C121608353 @default.
• W4304892381 hasConceptScore W4304892381C126322002 @default.
• W4304892381 hasConceptScore W4304892381C141071460 @default.
• W4304892381 hasConceptScore W4304892381C143998085 @default.
• W4304892381 hasConceptScore W4304892381C146357865 @default.
• W4304892381 hasConceptScore W4304892381C150173356 @default.
• W4304892381 hasConceptScore W4304892381C151730666 @default.
• W4304892381 hasConceptScore W4304892381C2776694085 @default.
• W4304892381 hasConceptScore W4304892381C2777416452 @default.
• W4304892381 hasConceptScore W4304892381C2777546739 @default.
• W4304892381 hasConceptScore W4304892381C2777632260 @default.
• W4304892381 hasConceptScore W4304892381C2777982462 @default.
• W4304892381 hasConceptScore W4304892381C2778938455 @default.
• W4304892381 hasConceptScore W4304892381C2780427987 @default.
• W4304892381 hasConceptScore W4304892381C509974204 @default.
• W4304892381 hasConceptScore W4304892381C71924100 @default.
• W4304892381 hasConceptScore W4304892381C86803240 @default.
• W4304892381 hasFunder F4320307770 @default.
• W4304892381 hasFunder F4320307773 @default.
• W4304892381 hasFunder F4320307779 @default.
• W4304892381 hasFunder F4320309470 @default.
• W4304892381 hasFunder F4320315087 @default.

• next